Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial



: Mesia R, Henke M, Fortin A, Minn H, Ancona ACY, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan ATC, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J

Publisher: ELSEVIER SCIENCE INC

: 2015

: Lancet Oncology

: LANCET ONCOLOGY

: LANCET ONCOL

: 16

: 2

: 208

: 220

: 13

: 1470-2045

DOI: https://doi.org/10.1016/S1470-2045(14)71198-2


Interpretation In patients with locally advanced squamous-cell carcinoma of the head and neck, the addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit, and the role of EGFR inhibition in these patients needs to be reassessed.




Last updated on 2024-26-11 at 23:37